rxstatShortages › Montelukast

Montelukast (Singulair) shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Jul 29, 2026

Some Montelukast products are in shortage in Canada (8 of 44 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Jun 30, 2027.

An asthma and allergy medication used to prevent asthma symptoms and treat seasonal allergies.

Products affected
8 / 44
In shortage since
Apr 18, 2019
Est. full return
Jun 30, 2027
Reports on file
119
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Book a pharmacist appointment
Need your prescription switched?
If your product stays unavailable, an online doctor can assess your situation and prescribe an alternative.
See a doctor online

Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.

Shortage history

2023 2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

Active shortage
PMS-MONTELUKAST FC
10MG · TABLET · PHARMASCIENCE INC
DIN 02373947 · since Jul 10, 2026, est. end Aug 7, 2026 · Disruption of the manufacture of the drug.
Active shortage
NAT-MONTELUKAST
10MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02522136 · since Jul 1, 2025, est. end Jun 30, 2027 · Not adequate demand for this product
Active shortage
NAT-MONTELUKAST
4MG · TABLET (CHEWABLE) · NATCO PHARMA (CANADA) INC
DIN 02522101 · since Apr 30, 2024, est. end Dec 31, 2026 · Long Term Back Order
Active shortage
NAT-MONTELUKAST
5MG · TABLET (CHEWABLE) · NATCO PHARMA (CANADA) INC
DIN 02522128 · since Apr 30, 2024, est. end Dec 31, 2026 · Long Term Back Order
Active shortage
ACH-MONTELUKAST
10MG · TABLET · ACCORD HEALTHCARE INC
DIN 02379236 · since May 3, 2024, no end estimate · Requirements related to complying with good manufacturing practices.
Active shortage
JAMP-MONTELUKAST
4MG · TABLET (CHEWABLE) · JAMP PHARMA CORPORATION
DIN 02442353 · since May 31, 2022, est. end Dec 31, 2023 · new DIN available (02514877)
Active shortage
JAMP-MONTELUKAST
5MG · TABLET (CHEWABLE) · JAMP PHARMA CORPORATION
DIN 02442361 · since May 12, 2022, est. end Dec 31, 2023 · new DIN available (02514885)
Active shortage
MONTELUKAST
4MG · TABLET (CHEWABLE) · SANIS HEALTH INC
DIN 02379317 · since ?, no end estimate · Disruption of the manufacture of the drug.
Active shortage
MONTELUKAST
4MG · TABLET (CHEWABLE) · SANIS HEALTH INC
DIN 02379317 · since Apr 18, 2019, no end estimate · Disruption of the manufacture of the drug.
Resolved
SINGULAIR
5MG · TABLET (CHEWABLE) · ORGANON CANADA INC.
DIN 02238216 · ended Jul 14, 2026 · Delay in shipping of the drug.
Resolved
SINGULAIR
10MG · TABLET · ORGANON CANADA INC.
DIN 02238217 · ended Mar 11, 2026 · Requirements related to complying with good manufacturing practices.
Resolved
APO-MONTELUKAST
10MG · TABLET · APOTEX INC
DIN 02374609 · ended Feb 26, 2026 · Disruption of the manufacture of the drug.

Showing 12 of 60 reports. All reports are on file with Health Canada.

What's happening

Montelukast is currently affected by 8 active shortage reports filed with Health Canada by PHARMASCIENCE INC, NATCO PHARMA (CANADA) INC, ACCORD HEALTHCARE INC, JAMP PHARMA CORPORATION and 1 others.

The reported causes are: disruption of the manufacture of the drug; not adequate demand for this product; long term back order; requirements related to complying with good manufacturing practices; new din available (02514877); new din available (02514885). Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Montelukast is classified under “OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES” (ATC R03DC).

Recent changes

Common questions

What is Montelukast used for?

An asthma and allergy medication used to prevent asthma symptoms and treat seasonal allergies.

When will Montelukast be back in stock in Canada?

The latest manufacturer estimate is Jun 30, 2027. Estimates are self-reported and often slip; this page updates automatically when they change.

Why is Montelukast in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Possible alternatives in the same class (other systemic drugs for obstructive airway diseases)

Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.